Eli Lilly and Company is seeking regulatory approval for its obesity medicines while expanding coverage through PBMs.
4 reports, 4 independent
Updated Aug 4
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly and Company is seeking regulatory approval for its obesity medicines while expanding coverage through PBMs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Cantor Fitzgerald lowered its price target for Eli Lilly and Company following data related to its obesity medicines.Sub-event
Lilly is seeking FDA approval for obesity medicines and expanding coverage via PBMs.1 source
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Caremark
Care franchise based in the United Kingdom
Nothing else this week.
- FDA
Related events
- Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.
- Eli Lilly and Novo Nordisk have both developed anti-obesity drugs, intensifying competition in the weight loss market.
- Eli Lilly and Company has achieved market leadership in the obesity and diabetes treatments sector.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.